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Summary
Intra-articular corticosteroids are an effective treatment for
equine osteoarthritis, however, there is increasing evidence
for the effectiveness of other treatments such as biologics.
Whilst current evidence does support biologics and their use
in patients diagnosed with osteoarthritis, there remains to be
a lack of evidence regarding their long-term outcomes and
the efficacy of their use as a treatment, especially when
compared to corticosteroids. This paper reviewed the
evidence comparing intra-articular corticosteroids and
biologics in the treatment of equine osteoarthritis and found
that whilst they are both effective treatments, more evidence
directly comparing them is required.
Refining the question
Do biologics, such as autologous conditioned serum and
autologous processed plasma, show an improved clinical
outcome (defined as a reduction in lameness and/or fewer
co-morbidities) and prognosis compared to corticosteroids
when treating osteoarthritis in equids?
Strategy for searching the evidence
For both corticosteroids and biologics, three databases were
searched on 18/11/2019; CAB Direct, Scopus and PubMed.
Full search strategies can be seen in Table 1 with inclusion
and exclusion criteria found in Table 2.
Quality and quantity of evidence found
From searching the aforementioned databases and applying
the inclusion and exclusion criteria (Table 2), four articles on
biologics and five papers on corticosteroids were used in this
critical appraisal. All articles on biologics were prospective
randomised controlled trials (Table 3). For corticosteroids, four
articles were prospective studies (two of which were
randomised) and one a retrospective nonrandomised study.
TABLE 1: Three databases were systematically searched for terms
relating to equine, biologics and corticosteroids
Journal Biologics search Corticosteroids search
CAB
Direct
(horse or equine or equid)
AND (osteoarthritis or
OA) AND (intra-articular
or IA) AND (IRAP or
interkeukin-1 receptor
antagonist)










Scopus (horse or equine or equid)
AND (osteoarthritis or
OA) and (intra-articular
or IA and IRAP or
interleukin-1 receptor
antagonist)














OA)) AND (IRAP OR
interleukin-1 receptor
antagonist)











TABLE 2: Exclusion and inclusion criteria which were applied to
studies on interleukin-1 receptor antagonist protein biologics and
corticosteroids
Biologics
Inclusion Relevant to the question, multi-animal study, in vivo
study, papers from 2004 onwards, uses biologics for
treatment of OA.
Exclusion Treatment other than IRAP or other biologics, papers
that are not relevant to the question, papers that
are not in English, single case studies, in vitro
studies and duplicates.
Corticosteroids
Inclusion Relevant to the question, multi-animal study, in vivo
study, papers from 1997 onwards, uses
corticosteroids for treatment of OA.
Exclusion Treatment other than corticosteroids, papers that are
not relevant to the question, in vitro studies, papers
not in English, single case reports and duplicates.
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These articles consisted of one cohort study and four clinical
trials, of which one was blinded (Table 4).
Overall, the quality of these papers was good (Murad
et al. 2016).
Can this evidence be applied to my case
population and conclusions?
Currently, there are no studies that directly compare the
effectiveness of biologics and corticosteroids when treating
equine osteoarthritis (OA). Corticosteroids are commonly used
as a therapy for osteoarthritis in horses and, in general, can be
very effective. Their efficacy is dependent on the
corticosteroid used, the dose administered, the type of joint,
the duration of treatment and the degree of pathology within
the joint. Corticosteroids act at the level of phospholipase A2
to block the production of inflammatory mediators produced
from the cyclooxygenase and lipoxygenase pathways as well
as having many other anti-inflammatory effects (Clegg and
Booth 2000). In general, it seems like corticosteroids combined
with hyaluronan or PSGAGs are usually effective in early stages
of OA (Richardson and Dyson 2011). In comparison, biologics
such as autologous conditioned serum are seen to work at a
more specific part of the inflammatory pathway to increase
anti-inflammatory cytokine concentrations (Hraha et al. 2011).
An example would be the interleukin-1 (IL-1) receptor
antagonist. IL-1 is a cytokine involved in the pro-inflammatory
pathway, and so by minimising its effect as well as providing
anti-inflammatory mediators, it promotes a homeostatic
environment within the joint.
During the last decade, treatments for osteoarthritis using
biologics have become increasingly more popular with their
use growing in frequency, and with favourable anecdotal
results (Richardson and Dyson 2011). In one study out of 428
practitioners, 36.2% use biologics when patients were
nonresponsive to corticosteroids (Ferris et al. 2011). However,
Ferris et al. draw on practitioners’ choice of treatment for
equine OA and so it is important to consider factors that will
affect those choices, such as efficacy, marketing and client
desires.
Whilst this critically appraised topic (CAT) was originally
comparing the efficacy of corticosteroids vs. biologics, the
issue of treatment timing became evident. One hypothesis is
that biologic treatments are typically started later in the
disease process where other treatment options have failed.
Therefore, the OA will have progressed to a point where
other treatment options may also struggle to provide an
improved clinical outcome. Without further studies implicating
the use of biologics as a treatment when clinical signs first
present, it is difficult to ascertain their effectiveness as a first-
line treatment, and so further studies relating to the stage of
OA that biologics are used for treatment are required.
Another factor limiting the use of biologics is their increased
cost (Nelson and Goodrich 2014) in comparison with
corticosteroids; in one study, Orthokine (an autologous
conditioned serum) was mainly used in the treatment of joint
pain when cost was of no issue to clients (Ferris et al. 2011).
Without substantial evidence proving its efficacy in early OA,
it is understandable that it is not used preferentially over
corticosteroids.
It should be noted that some of the studies presented here
were investigating experimentally induced OA. However,
similar improved clinical outcomes were found whether the
animal being treated had naturally occurring or induced OA.
TABLE 3: Following the exclusion/inclusion criteria being applied to the search results, four articles studying interleukin-1 receptor








Investigated the treatment of experimentally induced osteoarthritis (OA) in horses
with either autologous conditioned serum (ACS) or placebo (Phosphate Buffered
Saline; PBS) as control. 16 horses were split into two groups of 8; placebo (PBS) or
treatment (ACS). The two treatment groups were divided further with 4 having OA
induced into one middle carpal joint with the other a sham operated treatment.
All had intra-articular injections at 14, 21, 28- and 35-day intervals. Those in the ACS
treatment group received ACS into the OA induced joint and placebo into the
other sham-operated joint. Those in the control group all received PBS. Looking at
clinical, biochemical and histological parameters there was a significant








Investigated the treatment of osteoarthritis in 40 client-owned horses with either a
placebo of 0.9% saline solution or autologous conditioned protein solution (APS).
Treatment groups were broken down into two groups; APS treatment group
(n = 20) and saline control group (n = 20). Results showed that lameness grades
were significantly improved in the joints of the APS treatment group compared to







Evaluating the effectiveness of two ACS protocols of which frequency of intra-
articular ACS injection is being explored. 12 horses were split into two groups:
• Group 1: 1 intra-articular injection of ACS given every week for 3 weeks.
• Group 2: 3 intra-articular injections of ACS were given at 2-day intervals
It was found that whilst 2-day interval dosing appeared to be slightly advantageous
over a weekly dosing regimen due to the increases in IL-1ra and a decrease in IL-
1b, further studies should be carried out.
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One study investigated the effects of corticosteroids on the
treatment of induced synovitis (Todhunter et al. 1998). This
study was included as whilst it is not a direct model of OA,
synovitis has been implicated in the structural degradation of
the joint during OA pathogenesis (Wenham and Conaghan
2010) and the progression of OA (McIlwraith et al. 2012). Due
to this, the investigation of corticosteroids on synovitis is
relevant to this CAT.
In conclusion, corticosteroids can be an effective first-line
treatment, with biologics being used when corticosteroids fail
or when funds are less restricted. However, due to the lack of
literature directly comparing biologics and corticosteroids in
the treatment of OA, further studies should be carried out
earlier on in the disease process to compare the two
treatments. Studies could focus on directly comparing the
efficacy of biologics and corticosteroids when administered
in early OA, deleterious or positive effects on joint
pathophysiology, return to clinical soundness, and long-term
efficacy.
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TABLE 4: Following the exclusion/inclusion criteria being applied to the search results, five articles studying corticosteroids were








18 horses aged 2–7 years were used in this study; each had an osteochondral chip
fragment induced into a randomly assigned intercarpal joint, they were then
randomly assigned to one of three treatment groups.
Group 1: placebo control. Bilateral treatment of intra-articular polyionic fluid was
performed into the intercarpal joint.
Group 2: Triamcinolone Acetonide (TA) control group. Intra-articular polyionic was
injected into joints where a chip fragment had been created. TA fluid was also
injected in the contralateral intercarpal joint. Group 3: TA treatment group where
intra-articular TA was injected into the chip fragmented joint and the
contralateral intercarpal joint was injected with polyionic fluid.
Compared with horses in the control and TA control groups, horses in the TA
treatment group were significantly less lame. Both intra-articular and remote site
administration had favourable effects on synovial fluid, synovial membrane and






In this study, synovitis was induced in 10 ponies with lipopolysaccharide (LPS).
Methylprednisolone acetate (MPA) alone was injected into select joints, and LPS
with MPA injections administered at the final administration to the treatment
group to investigate presence of pathological changes against an LPS control
group.
There was no significant difference between groups on histopathology. However,
both LPS and LPS/MPA treatments groups had moderate to severe inflammatory
changes compared to the MPA treated and control group which had mild to no
inflammatory changes. In the MPA treatment group there was increased protein






Investigated intra-articular treatment with corticosteroids alone or intra-articular
corticosteroids with hyaluronate (HA) into distal tarsal joints in 51 horses,
hospitalised with lameness due to osteoarthritis.
The greatest improvement was observed in those that had mild to moderate signs
of osteoarthritis in the tarsometatarsal and centrodistal joints, as well as those that






This study investigated 80 client owned horses with a clinical history of osteoarthritis.
Two treatment groups were examined for clinical soundness; one group was
treated with intra-articular TA alone and the other treated with intra-articular TA
and HA.
Those treated with TA and HA achieved a success rate of 64.1% compared to TA
treatment with a success rate of 87.8% with success being defined as a reduction
in lameness and effusion scores.
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